Back to top
more

DaVita (DVA)

(Delayed Data from NYSE)

$161.97 USD

161.97
575,208

+1.87 (1.17%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $161.95 -0.02 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 6% (16 out of 250)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Fresenius Medical (FMS) Divests Businesses to Optimize Portfolio

by Zacks Equity Research

Fresenius Medical (FMS) streamlines for success with three key divestments in 2023. These divestments are likely to impact operating income by EUR 500 million in the fourth quarter.

Here's Why You Should Retain National Vision (EYE) Stock Now

by Zacks Equity Research

Investors are optimistic about National Vision's (EYE) stock, banking on strong solvency and promising future strategies.

Tandem Diabetes (TNDM) and Abbott Debut New Integrated Offering

by Zacks Equity Research

Tandem Diabetes' (TNDM) t:slim X2 is the first AID system to be integrated with Abbott's Freestyle Libre 2 Plus sensor.

Best Growth Stocks to Buy for January 9th

by Zacks Equity Research

EG, BROS and DVA made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 9, 2024.

Illumina (ILMN) Extends Partnership to Advance Cancer Test

by Zacks Equity Research

Illumina (ILMN) aims to work with other pharmaceutical industry leaders to enhance and expand the utility of its WGS MRD assay.

Here's Why Investors Should Retain Abbott (ABT) Stock Now

by Zacks Equity Research

Investors are optimistic about Abbott (ABT) led by solid prospects in the Diagnostic business and raised guidance.

Chemed (CHE) Roto-Rooter Growth Continues, Macro Issues Hurt

by Zacks Equity Research

Within the Hospice segment, Chemed (CHE) is well poised to register growth driven by the growing aging population.

Asensus Surgical (ASXC) Completes Surgeon Lab for LUNA

by Zacks Equity Research

Asensus Surgical's (ASXC) latest Surgeon Lab helps it move closer to a finalized LUNA product.

Here's Why You Should Retain Accuray (ARAY) Stock for Now

by Zacks Equity Research

The continued solid demand for Accuray's (ARAY) products raises optimism about the stock.

AngioDynamics (ANGO) Q2 Earnings Top Estimates, Revenues Miss

by Zacks Equity Research

AngioDynamics (ANGO) registers strong revenue growth in the Med Tech business in second-quarter fiscal 2024.

Boston Scientific (BSX) Rides on Global Growth Amid Macro Woes

by Zacks Equity Research

Within APAC, Boston Scientific (BSX) is registering strong growth in Japan and China.

Avanos (AVNS) Preliminary Q4 Revenues Dampened by Lower Sales

by Zacks Equity Research

Avanos' (AVNS) revenue growth in the fourth quarter is likely to have been dampened by lower HA pain relief injection product sales.

Veradigm's (MDRX) Acquires Koha Health to Solidify Market Presence

by Zacks Equity Research

Veradigm's (MDRX) acquisition of Koha Health will likely enhance its ability to deliver efficient revenue cycle services by incorporating Musculoskeletal Medicine specialty subject matter expertise.

Bruker's (BRKR) New Deal Widens Biopharma PAT Product Portfolio

by Zacks Equity Research

Bruker (BRKR) announces the acquisition of Tornado Spectral Systems Inc., a global provider of chemical analysis & measurement systems for Raman spectroscopy.

Reasons to Retain The Cooper Companies (COO) in Your Portfolio Now

by Zacks Equity Research

The Cooper Companies (COO) benefits from strength in its business segments. Its acquisitions are likely to drive the top line. A rise in selling, general and administrative expenses is concerning.

Best Growth Stocks to Buy for January 5th

by Zacks Equity Research

BROS, DVA and EVBG made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 5, 2024.

Walgreens Boots (WBA) Q1 Earnings Top Estimates, Margins Down

by Zacks Equity Research

Walgreens Boots' (WBA) comparable pharmacy sales in the fiscal first quarter benefited from higher branded drug inflation and strong execution in pharmacy services.

Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now

by Zacks Equity Research

Investors are optimistic about Myriad Genetics (MYGN) on robust testing volumes and strong solvency position.

McKesson (MCK) Hits 52-Week High: What's Driving the Stock?

by Zacks Equity Research

Investors are optimistic about McKesson's (MCK) strength in its Biologics business.

Enovis (ENOV) to Strengthen Portfolio Via Its Latest Buyout

by Zacks Equity Research

Enovis' (ENOV) latest buyout is expected to expand its international scale with a complementary global customer base and product mix and improve efficiency with innovative manufacturing facilities.

Bruker (BRKR) Expands Materials Science Research via New Deal

by Zacks Equity Research

Bruker (BRKR) announces the acquisition of the electron microscopy company Nion.

Here's Why Investors Should Retain STERIS (STE) Stock for Now

by Zacks Equity Research

Investors continue to remain optimistic about STERIS (STE) due to the prospects of the healthcare business.

Reasons to Retain Stryker (SYK) Stock in Your Portfolio Now

by Zacks Equity Research

Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio.

Reasons to Hold West Pharmaceutical (WST) in Your Portfolio Now

by Zacks Equity Research

West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.

Haemonetics (HAE) Up 11% in a Year: Will the Rally Continue?

by Zacks Equity Research

Investors are optimistic about Haemonetics (HAE) owing to its strategic focus on establishing leading positions in high-growth markets and raised guidance.